Oxford Nanopore Technologies sign Non-Exclusive licensing agreement Genetics Research


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Oxford Nanopore Technologies sign Non-Exclusive licensing agreement Genetics Research
Oxford Nanopore Technologies Sign Non-Exclusive Licensing Agreement for Genetics Research’s Patented DNA Negative Enrichment Technology Platform

Genetics Research, LLC (“GR”), a privately-held company developing a portfolio of novel and proprietary CRISPR-associated technologies for targeted DNA enrichment, announced today that it has licensed certain of its patents relating to this technology to Oxford Nanopore Technologies, Ltd. (“Oxford Nanopore”) based in Oxford, United Kingdom. This license enables Oxford Nanopore to use GR patents to enhance certain offerings on its proprietary nanopore DNA/RNA sequencing platform. Terms of the non-exclusive license agreement were not disclosed.

“We are delighted to have signed this agreement with Oxford Nanopore,” said Anthony P. Shuber, President and COO of GR. “This is one part of GR’s patent portfolio, which represents a completely new approach to targeting long DNA fragments for sequence-specific enrichment. Enriching sequence-specific long DNA is complementary to sequencing platforms with the capability to analyze long fragments, and we are excited that Oxford Nanopore will be integrating this method into certain workflows on its sequencing technology.”

“GR’s novel negative enrichment approach has exciting potential synergy with Oxford Nanopore’s platform,” commented Dr Gordon Sanghera, CEO of Oxford Nanopore. “Nanopore sequencing enables users to sequence native long fragments of nucleic acids, capturing multiple variants including complex structural variation and methylation in the same experiment. Delivering targeted approaches for these analyses allows users to focus on specific genomic regions that might be of interest, and to multiplex multiple samples in a single run. This offers users a roadmap to exploiting these novel markers in clinical research across large sample cohorts. Partnering with innovators like GR is important as we introduce new ways of performing rapid, near-sample targeted sequencing to the market.”

GR’s novel and proprietary CRISPR-based enrichment platform provide multiple opportunities to enhance the field of genomic analysis. In addition to its long DNA technologies, GR has developed next-generation targeted enrichment technologies that complement PCR and hybrid capture when applied to both long and short DNA fragments. These technologies have applications across both the life sciences and diagnostics spaces, including sequence-specific multiplex analyses in FFPE, and liquid biopsies.

Genetics Research develops innovative and proprietary technologies for the development of products supporting genomic analysis in research, diagnostics, and therapeutics. Oxford Nanopore was spun out of the University of Oxford and has since developed and brought to market a new generation of tools for biological analysis.

Tags : #OxfordNanoporeTechnologies #GeneticsResearch #NonExclusiveLicensingAgreement #LatestPharmanewsUpdatesSep23 #DNANegativeEnrichmentTechnology #DNATechnologies

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026